What the Research Shows About Tysabri and PML Risk

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Literacy to Occupational Exposure Concerns

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance and post-market surveillance have established a clear link between Tysabri and PML, with risk factors including JC virus antibody status and duration of therapy. This page summarizes published case reports, FAERS data, and FDA labeling to help you understand the evidence and what it means for monitoring and risk management.

Clinical Evidence: Tysabri and PML

Building on the occupational exposure context, it is essential to examine the clinical evidence linking Tysabri (natalizumab) to Progressive Multifocal Leukoencephalopathy (PML). Tysabri is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented association with PML, a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling to describe the clinical presentation, pharmacological context, mechanistic pathways, and risk considerations relevant to this adverse event. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition arises from reactivation of the JC virus, which infects oligodendrocytes and causes progressive demyelination. Clinical manifestations may include new or worsening neurological symptoms such as cognitive changes, motor deficits, visual disturbances, or seizures. Diagnosis relies on neuroimaging, typically MRI showing multifocal white matter lesions, and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because the disease can progress rapidly.

Pharmacology and Adverse Effects of Tysabri

Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrin, inhibiting leukocyte adhesion and migration into inflamed tissues. This mechanism reduces inflammatory activity in multiple sclerosis and Crohn's disease but also impairs immune surveillance in the central nervous system. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In clinical trials, PML occurred in three patients: two among 1869 multiple sclerosis patients treated for a median of 120 weeks (both had received Tysabri in addition to interferon beta-1a), and one among 1043 Crohn's disease patients after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other adverse reactions include headache, influenza-like illness, peripheral edema, infections, and thrombocytopenia (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanistic Pathways Linking Tysabri to PML

The pathogenesis of Tysabri-associated PML involves impaired immune surveillance. By blocking alpha-4 integrin, Tysabri prevents lymphocytes from crossing the blood-brain barrier, reducing the ability to control JC virus replication in the brain. This mechanism is supported by the observation that PML risk increases with longer treatment duration and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The JC virus is latent in many individuals, and immune suppression allows reactivation. The presence of anti-JCV antibodies is a key risk factor, as it indicates prior exposure to the virus (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Risk Anchors: Warnings, Causation, and Timeline

The adequacy of warnings regarding Tysabri and PML is addressed through a boxed warning and a restricted distribution program called TOUCH (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning explicitly states that Tysabri increases PML risk and identifies three risk factors: anti-JCV antibody positivity, longer treatment duration (especially beyond two years), and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately if such symptoms appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For affected patients, causation considerations involve assessing the presence of risk factors and the temporal relationship between Tysabri exposure and PML onset. The labeling notes that PML occurred in clinical trials after varying durations: two multiple sclerosis patients after a median of 120 weeks and one Crohn's disease patient after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline underscores that PML can occur early or late in treatment. The labeling also advises that Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors in Crohn's disease, as this may further elevate risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In summary, the evidence establishes a clear causal link between Tysabri and PML, mediated by impaired immune surveillance. The FDA-approved labeling provides detailed warnings and risk stratification, emphasizing the need for careful patient selection, monitoring, and prompt intervention. Patients and clinicians must weigh the therapeutic benefits against the risk of this severe adverse event.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) increases the risk of PML, a severe brain infection caused by the JC virus. The FDA-approved labeling includes a boxed warning about this risk. PML occurs due to impaired immune surveillance in the central nervous system, as Tysabri blocks lymphocyte migration across the blood-brain barrier (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the risk factors for developing PML while on Tysabri?

Three key risk factors are identified: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

How is PML diagnosed in patients taking Tysabri?

Diagnosis involves neuroimaging (MRI showing multifocal white matter lesions) and detection of JC virus DNA in cerebrospinal fluid. Clinical symptoms may include cognitive changes, motor deficits, visual disturbances, or seizures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.